The French drugmaker Sanofi Pasteur has declared to accelerate a vaccine development timeline that may receive approval from regulatory authorities in the first half of 2021.
The company and the partner GlazoSmith Kline (GSK) announced the availability of the vaccine at the earliest, most probably in the latter half of next year.
Developing shots for COVID-19 and the flu in a deal is expected to be valued at as much as $ 2.3 billion. Concerning the Sanofi Corona virus vaccine trial, Sanofi has announced his plan to invest 610 million Euros for expanding vaccine business with two new products and research centers in its home market.
As per the agreement, Sanofi will get worldwide rights for developing infectious disease vaccines. Sanofi confirmed to have multiple COVID-19 vaccine candidates and expected to begin the clinical trials with humans in the fourth quarter of this year.
A very few numbers of volunteers were involved in Phase I vaccine trials but will increase this number to secure more reliable data sooner, said Sanofi.
Finding the right vaccine to treat COVID-19 is the first stage; the major challenge lies in the production and distribution of the product globally.
The Sanofi-GSK vaccine has a laboratory-synthesized version of the coronavirus’s “spike” protein, which is essential to enter host cells. The recombinant vaccine also contains GSK’s proprietary adjuvant that can enhance the body’s immune system to a foreign onslaught.
Also, Sanofi is preparing a different set of vaccine candidates with Translate Bio, an American therapeutics company. Based on mRNA technology, which has already been used by Sanofi’s competitors, including Moderna and a partnership between BioNTech, Pfizer, and Fosun Pharma.
Thomas Triomphe (Executive vice president at vaccines unit) states, “We strongly believe that the addition of mRNA platform to the vaccine development capabilities will prevent the world from various infectious diseases.”
The mRNA vaccines are under preclinical testing and expected to be ended by 2020 with a hope to receive approval from regulatory bodies such as the U.S Food and drug administration or the European Medicines Agency by the end of 2021.
It will be a huge success if the efforts of Sanofi and its partners meet the mark.
The severity of the disease makes people around the world impatiently waiting to get the right vaccine to stop it. A vaccine against COVID 19 will make your immune system create antibodies that will prevent you from falling sick and, thus, could save the lives.
As per the World Health Organization, It is like more than 100 vaccines are in different stages of development around the world. Even if researchers remain successful in bringing the right vaccine, then also 12 to 18 months will be required to make it ready for the public. The vaccine must go through development and testing to confirm its effectiveness against the virus or bacteria and to make sure that it does not cause other problems.